The Japan Times - 'Remarkable global progress': HIV cases and deaths declining

EUR -
AED 3.825399
AFN 79.153772
ALL 98.736666
AMD 415.287403
ANG 1.877402
AOA 952.448759
ARS 1090.834985
AUD 1.659602
AWG 1.877301
AZN 1.773879
BAM 1.950918
BBD 2.103246
BDT 127.032085
BGN 1.954353
BHD 0.392577
BIF 3035.968151
BMD 1.041499
BND 1.409579
BOB 7.197814
BRL 6.181396
BSD 1.041698
BTN 90.061042
BWP 14.407873
BYN 3.408985
BYR 20413.370758
BZD 2.092473
CAD 1.496639
CDF 2963.063339
CHF 0.944473
CLF 0.037424
CLP 1032.625104
CNY 7.574405
CNH 7.583047
COP 4438.460457
CRC 523.891405
CUC 1.041499
CUP 27.59971
CVE 110.714893
CZK 25.152813
DJF 185.095046
DKK 7.460863
DOP 63.958481
DZD 140.701185
EGP 52.405391
ERN 15.622478
ETB 131.280745
FJD 2.408725
FKP 0.857765
GBP 0.845695
GEL 2.967827
GGP 0.857765
GHS 15.832891
GIP 0.857765
GMD 76.029524
GNF 9015.210639
GTQ 8.051849
GYD 217.831709
HKD 8.1117
HNL 26.568478
HRK 7.685788
HTG 136.030219
HUF 410.555067
IDR 16929.766548
ILS 3.691409
IMP 0.857765
INR 90.040306
IQD 1364.363046
IRR 43847.087052
ISK 146.070191
JEP 0.857765
JMD 163.450942
JOD 0.738837
JPY 163.128346
KES 134.870181
KGS 91.079163
KHR 4198.280235
KMF 492.212582
KPW 937.348773
KRW 1496.049575
KWD 0.321084
KYD 0.868123
KZT 542.644563
LAK 22704.667648
LBP 93318.266805
LKR 311.072991
LRD 203.040547
LSL 19.26565
LTL 3.075274
LVL 0.629992
LYD 5.129371
MAD 10.43556
MDL 19.427287
MGA 4952.325547
MKD 61.527275
MMK 3382.746528
MNT 3539.012042
MOP 8.356147
MRU 41.503932
MUR 48.377901
MVR 16.044292
MWK 1806.999849
MXN 21.375127
MYR 4.620606
MZN 66.55058
NAD 19.267918
NGN 1621.613087
NIO 38.225035
NOK 11.745775
NPR 144.098067
NZD 1.838236
OMR 0.400889
PAB 1.041698
PEN 3.872817
PGK 4.142028
PHP 60.981759
PKR 290.213572
PLN 4.222409
PYG 8239.379829
QAR 3.791571
RON 4.974506
RSD 117.103005
RUB 103.370761
RWF 1447.682926
SAR 3.906769
SBD 8.819417
SCR 15.731842
SDG 625.940544
SEK 11.464035
SGD 1.411538
SHP 0.857765
SLE 23.694484
SLL 21839.702882
SOS 595.18962
SRD 36.53548
STD 21556.91634
SVC 9.115188
SYP 13541.563586
SZL 19.270615
THB 35.280778
TJS 11.400894
TMT 3.645245
TND 3.328112
TOP 2.439295
TRY 37.129316
TTD 7.076325
TWD 34.071066
TZS 2629.783534
UAH 43.751107
UGX 3833.424736
USD 1.041499
UYU 45.585915
UZS 13534.272674
VES 57.522481
VND 26131.197567
VUV 123.648794
WST 2.917057
XAF 654.32261
XAG 0.033809
XAU 0.000378
XCD 2.814702
XDR 0.802595
XOF 657.185531
XPF 119.331742
YER 259.333095
ZAR 19.256229
ZMK 9374.731321
ZMW 29.036635
ZWL 335.362095
  • BCC

    -1.0700

    128.05

    -0.84%

  • CMSD

    -0.1110

    23.889

    -0.46%

  • CMSC

    -0.0350

    23.515

    -0.15%

  • BCE

    -0.1700

    23.22

    -0.73%

  • SCS

    -0.1550

    11.645

    -1.33%

  • RIO

    -0.2350

    61.495

    -0.38%

  • JRI

    -0.0100

    12.56

    -0.08%

  • RBGPF

    0.1600

    62.36

    +0.26%

  • NGG

    -1.3500

    60.24

    -2.24%

  • RYCEF

    0.1700

    7.44

    +2.28%

  • GSK

    -0.3400

    33.44

    -1.02%

  • AZN

    0.3000

    68.26

    +0.44%

  • RELX

    -0.2400

    49.31

    -0.49%

  • BTI

    -0.0760

    36.654

    -0.21%

  • VOD

    -0.1400

    8.41

    -1.66%

  • BP

    -0.2250

    31.295

    -0.72%

'Remarkable global progress': HIV cases and deaths declining
'Remarkable global progress': HIV cases and deaths declining / Photo: PRAKASH MATHEMA - AFP/File

'Remarkable global progress': HIV cases and deaths declining

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.

Text size:

But HIV is far from being stamped out, health experts warn ahead of World AIDS Day on Sunday.

- Uneven progress -

During the 2010s, the number of HIV infections across the world declined by a fifth, according to a major study published in The Lancet HIV journal on Tuesday.

Deaths related to HIV, which are generally caused by other diseases during the late stages of AIDS, fell by about 40 percent to below a million a year, the study said.

The decline was mainly driven by improving rates in sub-Saharan Africa, which is by far the hardest-hit region in the global epidemic.

However infections did not go down everywhere. Other regions, such as Eastern Europe and the Middle East, saw HIV numbers increase.

And the world remains far from the United Nations target of virtually eradicating AIDS-related deaths by 2030, the researchers said.

"The world has made remarkable global progress to significantly reduce the number of new HIV infections," said lead study author Hmwe Kyu of the US-based Institute For Health Metrics and Evaluation.

"More than a million people acquire a new HIV infection each year and, of the 40 million people living with HIV, a quarter are not receiving treatment," she said in a statement.

- Effective tools -

Preventative treatments called Pre-Exposure Prophylaxis (PrEP) have proven to be a powerful tool in the fight against HIV.

These daily pills reduce the risk of getting HIV from sex by around 99 percent.

They have helped drive down HIV rates in many countries. In some, such as France, health authorities are urging PrEP to be made more available to more people, rather than just men who have sex with men.

"It is something that can be used by anyone who needs it at some point in their sexual life," French infectious disease specialist Pierre Delobel told a press conference.

For people who have been infected with HIV, antiretroviral therapy can reduce the amount of the virus in their blood to undetectable levels.

An undetectable viral load means that there is less than a one percent chance that breastfeeding mothers pass HIV onto their babies, according to the US Centers for Disease Control and Prevention.

- New drug raises hopes -

These tools have worked well in wealthier countries but the high costs have meant that poorer countries -- such as in Africa -- have often been left behind.

There are fears that this history could repeat for a new drug that has been hailed as a potential game-changer in the battle against HIV.

Early trials have found that the antiretroviral treatment lenacapavir is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to administer than current regimens requiring daily pills.

US pharmaceutical giant Gilead has been charging around $40,000 per person per a year for the treatment in several countries.

But researchers have estimated the drug could be made for as little as $40, calling on Gilead to allow for cheaper access in hard-hit nations.

Last month, Gilead announced it had signed licensing deals with six generic drugmakers to produce and sell lenacapavir in lower-income countries.

While experts largely welcomed the move, some noted that millions of people with HIV live in countries not included in the deal.

The twice-yearly injection is also hoped to help get around another problem for administering HIV drugs -- the stigma that comes along with having the disease.

- What about a vaccine? -

Despite decades of effort, a vaccine for HIV remains elusive.

But the lenacapavir shot is "like having a vaccine basically", Andrew Hill, a researcher at the UK's Liverpool University, told AFP earlier this year.

A handful of patients have also been effectively cured of HIV.

But these cures happen only after a patient endures a brutal stem cell transplant for their leukaemia, so is not an option for almost all people living with HIV.

H.Nakamura--JT